The DELEE offering is now closed and is no longer accepting investments.

DELEE

Early cancer diagnosis and treatment monitoring

DELEE

Early cancer diagnosis and treatment monitoring

Laredo, TX
Biotechnology
Health Tech
At Delee, we have created the CytoCatch™️ isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.

$347,498

raised
$1,070,000
previously crowdfunded
500
Investors
$22M
Valuation
$1.66
Price per Share
$199.20
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$5M
Offering Max
0
Days Left

$347,498

raised
$1,070,000
previously crowdfunded
500
Investors
$22M
Valuation
$1.66
Price per Share
$199.20
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$5M
Offering Max
0
Days Left
This offering ended on April 07, 2022 and is no longer accepting investments.

Reasons to Invest

  • Blood-based assay for the early detection of cancer and monitoring of the applied treatments’ effectiveness, which is enabled by two independent devices created to effectively isolate and analyze circulating tumor cells (CTCs). Delee has a fully functional technology that is being successfully tested for prostate and breast cancer with pre-orders worth a potential value of over $2.5 million USD. 
  • Delee is backed by Y Combinator and StartX, and has raised over $2.4 million USD in funding. In 2020, the global circulating tumor cell market was valued at $8.4 billion USD, and it is expected to reach $18.3 billion USD by 2027.
  • We have built an experienced team of specialists in the fields of molecular biology, electronics, artificial intelligence, clinical oncology, product design, and manufacture.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

Since our last raise


Milestones Reached

  • We improved the capabilities of our previous prototypes to greatly increase the robustness and reliability of our CTC blood-based assay. 
  • We completed the commercial versions of the devices that enable the CTC blood-based assay. 
  • We expanded the number of collaborations with medical institutions, which will allow us to clinically validate our technology in less time.
  • We increased the number of processed patient samples to assess the feasibility of using our technology for various cancer-related clinical applications. 
  • We expanded our team in order to accelerate the commercial launch of our technology.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

The Problem



* Source


Cancer has become a major global health issue. According to the International Agency for Research on Cancer (IARC), in 2020, the number of new registered cases surpassed 19.2 M globally, whereas over 9.9 M deaths occurred due to this disease (Source). Despite all the recent breakthroughs in cancer treatments, it is estimated that by 2040, the number of new registered cases and fatalities per year will increase to 30.2 M and 16.3 M, respectively (Source, Source). The National Cancer Institute (NCI) estimates that 39.5% of Americans will be diagnosed with cancer at some point during their lifetime (Source), unfortunately, many of these people will lose their lives because of it. One of the main reasons cancer has such a high mortality rate is due to the current lack of tests with the required sensitivity and specificity to enable an early diagnosis of the disease. 


When it comes to cancer, the detection of tumors at an early stage is key because the survival rate in most types of cancer is directly related to the stage at which tumors are detected. For example, the 5-year relative survival rate for breast cancer when detected at early stages is 99%, but drops to 28% when detected at late stages (Source). Furthermore, early detection has the potential to reduce the financial burden of health care on individuals and public health services mainly because cancer treatments used for treating localized disease are less complex, and therefore, less expensive; according to the World Health Organization (WHO), studies made in high-income countries have shown that the cost of cancer treatment, when detected at early stages, is 2 to 4 times less expensive than at advanced stages (Source). 


Moreover, there is a lack of technological resources to provide effective monitoring of the applied cancer treatments’ efficacy, which may significantly reduce the patients’ chances of survival given that the right treatment at the right time for each cancer patient may not be administered due to the lack of information available for physicians. 


Since there is an unmet need for tests that can reliably detect cancer at early stages and monitor the applied treatments’ effectiveness, the research community has been actively searching for novel biomarkers that can provide clinical information for these purposes. The isolation of circulating tumor cells (CTCs) from blood is a recent alternative that could address this need. In the last decade, CTCs have attracted a significant amount of attention for their potential use as a blood-based biomarker for a broad range of cancer-related clinical applications. CTCs are malignant cells that are shed from the primary and/or metastatic solid tumors that infiltrate into the vascular and lymphatic systems; these cells play a fundamental role in the metastatic process of non-hematological cancers (Source, Source).



Technologies that detect and isolate CTCs from blood can be used to develop assays that could enable early cancer detection and monitor the applied treatments’ effectiveness. However, the isolation of these malignant cells from blood represents a major technological challenge due to their heterogeneity and extremely low numbers in comparison to blood cells (Source, Source); on average, you can find around 40.5 billion cells in 7.5 mL of blood, while a cancer patient may have between 1 and 1000 CTCs in the same volume (Source).

Even though there currently exists multiple cell sorting methods, such as fluorescent-activated cell sorting, magnetic-activated cell sorting, fluorescent-activated droplet sorting, and density gradient centrifugation, these are not compatible with whole blood samples and/or do not have the sufficient sensitivity and specificity to correctly isolate CTCs from blood, which have prevented the development of assays with potential clinical utility... until now.

Our Solution


At Delee, we have created the CytoCatch™  isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

How it works



For the assay, a single blood tube is extracted by conventional venipuncture (the collection method that is usually used for laboratory testing). The blood sample along with several reagents are loaded on the CytoCatch™  isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The unit has an outstanding performance, it has recovery rates above 94% when processing 7.5 mL blood samples spiked with tumor cells from prostate, breast, and colorectal cancer cell lines, meaning that the platform recovers at least 94 out of 100 tumor cells spiked into the sample (Source).


Once captured, the CytoCatch™  isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis with the CytoCatch™ imaging system, which possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human error and cell loss due to manual steps.


Furthermore, the collected cells are compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs. Finally, the treating physician will get a report with the corresponding results.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

ONCOLOGICAL CLINICAL APPLICATIONS



Our technology has the specificity and sensibility required to successfully isolate and analyze CTCs from blood, which may enable the following clinical applications:


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

BENEFITS OF OUR TECHNOLOGY



The early detection of cancer and the monitoring of the applied treatments’ effectiveness will be translated into invaluable benefits for patients and their families, being the most important, and the main reason for all our work, to greatly increase their chances of defeating cancer. Furthermore, monitoring the treatments’ effectiveness could also significantly increase the odds of defeating cancer by applying the most effective treatment for each patient throughout the course of the disease, while reducing the incurred costs and the negative side effects caused by drugs that wouldn’t be effective for a particular patient.


FOR WHAT TYPES OF CANCER?



Our technology can be used for a wide variety of cancer types. There is scientific evidence that indicates the feasibility of developing CTC assays to enable clinical applications in various types of cancer, including prostate, breast, colorectal, lung, cervical, skin, and ovarian cancer, just to name a few. Prostate, breast, colorectal, and lung cancer are responsible for over 40% of new cancer cases and a third of the deaths registered worldwide due to this disease (Source). 



Traction


Pre-orders worth a potential value of over $2.5 million USD

We’ve gotten great traction since the pre-commercial launch of our technology. To date, pre-orders worth a potential value of over $2.5 million USD have been secured from research centers of various hospitals in order to use our technology as an in vitro diagnostic platform for research use only, prior to FDA clearance.

Customers


Who buys it?

Prior to acquiring FDA clearance, Delee aims to commercialize the CytoCatch™ isolation platform and imaging system as research tools, being pharmaceutical companies and research centers our main customers. Once our technology obtains FDA clearance, it will be commercialized as an in vitro diagnostic medical device for hospitals and laboratories.


Business Model


Recurring revenue through consumable and reagent sales

Prior to FDA clearance, our devices will be commercialized as research tools, where the razor and blades business model will be followed, obtaining recurrent revenue by selling the necessary reagents and consumables to perform each test. This model will be maintained once FDA gives clearance for our technology to be commercialized as an in vitro diagnostic medical device for hospitals and laboratories.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.


Market


An $18.3 billion USD market by 2027

According to a recent report published by Grand View Research, in 2020, the global circulating tumor cell market was valued at $8.4 billion USD, and it’s expected to reach an $18.3 billion USD valuation by 2027 (Source, Source). This growth is mainly driven by the increase in the number of cancer cases that will occur in the coming years.  



At Delee, we are initially validating our technology for prostate and breast cancer, to later expand it to lung and colorectal cancer, mainly because, in 2020 alone, these four types of cancer account for over 40% of the new cancer cases registered worldwide and were responsible for over 3.7 million deaths (Source).

Competitors


A more effective way to capture and analyze CTCs

Most of the blood tests employed as auxiliaries in the diagnosis of cancer and monitoring of the applied treatments’ effectiveness measure protein tumor markers levels, such as PSA, CA-125, and AFP. However, there are only a few protein tumor markers that are associated with a particular cancer and are clinically useful; most types of cancer have not been linked to an increase in the levels of a particular protein tumor marker (Source). Furthermore, these types of tests have a poor sensitivity and specificity, meaning that these markers may be elevated in people that do not have cancer and that not every person with a particular type of cancer will have an elevated level of the corresponding tumor marker (Source). Taking the PSA test as an example, which measures the amount of PSA in blood and is used to screen for prostate cancer, approximately 66% of men with increased levels of PSA do not have prostate cancer, whereas over 15% of the men with normal levels of PSA may have prostate cancer (Source).      


The isolation and analysis of CTCs is a relatively new practice, and physicians are starting to recognize all its potential benefits. Most of the current CTCs technologies, including the CellSearch® System, which is considered the gold standard, rely on the existence of specific proteins on the tumor cell membrane in order to capture them. However, CTCs are incredibly heterogeneous; when entering the bloodstream, they undergo a biological process that downregulates these proteins, limiting the efficiency with which these cells are captured and thereby losing valuable information (Source, Source). Our technology changes the norm by isolating CTCs irrespective of the proteins expressed in their membranes, allowing us to capture tumor cells that other technologies simply can’t.



*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

Our Vision



Font Size
Drop image
(or click)

Uploading

Insert Image
Drop image
(or click)

Uploading

Insert Image
Drop image
(or click)

Loading image

Quick Insert
Drop image
(or click)

Loading image

Edit Link

Offering Summary


Company

:

DELEE CORP.

Corporate Address

:

1211 San Dario Ave #2068, Laredo, TX 78040

Offering Minimum

:

$9,999.84

Offering Maximum

:

$4,999,998.02

Minimum Investment Amount

(per investor)

:

$199.20











Terms


Offering Type

:

Equity

Security Name

:

Series Seed V Preferred Stock

Minimum Number of Shares Offered

:

6,024

Maximum Number of Shares Offered

:

3,012,047

Price per Share

:

$1.66

Pre-Money Valuation

:

$22,040,057.38











*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.

Investment Incentives*

Early Bird Bonus

Friends and Family - First 72 hours | 10% bonus shares

Super Early Bird - Next 7 days | 8% bonus shares

Early Bird Bonus - Next 10 days | 6% bonus shares

Volume-Based Bonus

$5,000 - 10% bonus shares

$10,000 - 12% bonus shares

$15,000 - 14% bonus shares

$20,000 - 16% bonus shares

$25,000 - 18% bonus shares

$30,000 - 20% bonus shares

*All perks occur when offering is complete.

The 10% StartEngine Owners' Bonus

Delee Corp. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series Seed V Preferred Stock at $1.66 / share, you will receive 10 additional shares, meaning you'll own 110 shares for $166. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

Example - The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$907,032.00 USD
$418,377.00 USD
Cash And Cash Equivalents
$344,289.00 USD
$1,594.00 USD
Accounts Receivable
$98,848.00 USD
$43,156.00 USD
Short Term Debt
$9,896.00 USD
$23,128.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$55,613.00 USD
Costs Of Goods Sold
$0.00 USD
$1,454.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$622,364.00 USD
-$91,803.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

The final 6 hours to become an investor in Delee!

4 months ago

The campaign is 6 hours away from finishing. Thank you for your support and your feedback during our SE campaign.


If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙



The final 12 hours to become an investor in Delee!

4 months ago

The campaign is 12 hours away from finishing. Thank you for your support and your feedback during our SE campaign.


If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙


The final 24 hours to become an investor in Delee!

4 months ago

The campaign is less than 24 hours away from finishing. Thank you for your support and your feedback during our SE campaign.


If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙


Only a day left to become an investor in Delee!

4 months ago

We’re close to the end of our campaign. From everyone working at Delee we would like to say that your support has been very important to all of us.

If you reserved during the TTW stage there is still time to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙


Meet the CytoCatch™ isolation platform, a powerful device for CTC isolation

4 months ago

Hello everyone!

Circulating tumor cells (CTCs) have attracted a significant amount of attention for their potential use as a blood-based biomarker to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment. The analysis of these cells will enable the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling. However, their heterogeneity and extremely low concentration in comparison to the other cellular components of blood, about 1–10 CTCs per billion blood cells, makes their capture extremely challenging… until now.

We have developed the CytoCatch™ isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The CytoCatch™ isolation platform has the sensitivity to isolate a single CTC from a background of 50 billion blood cells, isolating these malignant cells by leveraging the difference in size and deformability between CTCs and blood cells. Once captured, the CytoCatch™ isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis, allowing the identification of the patient’s tumor biological characteristics. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human error and cell loss due to manual steps. Furthermore, the CytoCatch™ isolation platform is  compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs.



We are so excited because we are only a few months away from being able to start commercializing our technology as a research use only device, for its use in research centers and pharma companies.

We want to take this opportunity to remind you that there are less than 48 hours left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙

3 days left to invest in Delee!

4 months ago

We’re almost reaching the end of our campaign. It has been heartwarming to know that many people believe in what we’re doing and most importantly that they believe in us.


For the people that reserved but did not confirm their investment remember that you still have this period of time to confirm and receive your bonus shares.


For our followers still on the fence about investing here is why we think you should invest in us


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙


4 days left to invest in Delee!

4 months ago

We’re almost reaching the end of our campaign. It has been heartwarming to know that many people believe in what we’re doing and most importantly that they believe in us.


For the people that reserved but did not confirm their investment remember that you still have this period of time to confirm and receive your bonus shares.


For our followers still on the fence about investing here is why we think you should invest in us


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙


Meet the CytoCatch™ imaging system, a powerful platform for CTC analysis

4 months ago

Hello everyone!

As you know, our technology is composed of two devices, the CytoCatch™ isolation platform, which processes the sample capturing the contained CTCs, and the CytoCatch™ imaging system, which performs the analysis of the captured cells. In this update we want to talk about some of the characteristics that make the CytoCatch™ imaging system an ideal platform for CTC analysis.

Once the sample has been processed, the substrate where the CTCs are captured is placed in the CytoCatch™ imaging system to enumerate CTCs and identify specific biological characteristics that give information to physicians about treatment selection and therapy response assessment. The CytoCatch™ imaging system has very unique characteristics that allow the complete mapping of the substrate area where the CTCs were captured, as shown in the video. This mapping is performed at different focal planes to ensure that all the cells are in focus, increasing the reliability of the analysis. Furthermore, the CytoCatch™ imaging system allows the fluorescence-based identification of up to 6 different markers in the captured cells, which gives the flexibility to create specific panels for a wide variety of cancers, providing valuable information to physicians regarding the identification of possible markers that serve as targets for targeted therapies. Finally, the CytoCatch™ imaging system has a powerful built-in AI that enumerates the captured CTCs and categorizes them based on their biological characteristics, thereby eliminating the subjective interpretation of operators and increasing the reproducibility of analysis, while decreasing the time needed to manually enumerate the CTCs captured.



We are so excited because we are only a few months away from being able to start commercializing our technology as a research use only device, for its use in research centers and pharma companies.

We want to take this opportunity to remind you that there are only 5 days left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙

Delee passes $300,000 in investments!

4 months ago

We are thrilled to announce that our campaign has passed $300k in investments, we are so happy to reach another milestone!

What we have accomplished has only been possible thanks to everyone who has joined our mission of revolutionizing cancer blood tests.

We are on the final days of our campaign, for those who reserved shares during the TTW stage, these are the last days you have to confirm your investment and receive your 10% bonus shares.

And if you haven't invested yet, you still have time to do so.


Delee Team 💙



1 week left to invest in Delee!

4 months ago

Hello everyone!

The final week of our campaign has started. To everyone that has supported us and has become an investor we would like to thank you for allowing us to continue our endeavor of helping people with cancer detection and treatment.

For those who reserved shares during the TTW stage, you still have this next week to confirm your investment and receive your 10% bonus shares.

And if you haven't invested yet, and you’re interested, you still have time to do so.

Thank you!


Delee Team 💙



The importance of Delee's platform for the personalization of cancer therapies

4 months ago

Hello everyone!

In this update we want to address a couple of questions many people ask us. 

1- Why is it important to personalize the therapies that are applied to cancer patients? 

The importance has to do with the mechanism of action of the new therapies that have been and are being developed to treat cancer. Most of these therapies are targeted therapies, which currently is one of the major modalities of medical treatment for cancer. The American Cancer Society defines a targeted therapy as a type of cancer treatment that uses drugs or other substances to precisely identify and attack certain types of cancer cells. These therapies target specific biological characteristics in the cells that make up the patient’s tumor. Consequently, in order to personalize the therapy of each patient, it is crucial to know which markers are expressed in the cells that make up the tumor of each patient to target them. And because cancer constantly undergoes mutations, it is equally important to keep obtaining information regarding these characteristics throughout the course of the disease, so physicians can apply the right treatment, at the right time, and in this way improve the patient's outcome. This is why we require technologies that allow the identification of markers, within tumor cells, that can be used as targets for newly developed therapies.



This leads us to the second question,  

2- How will your technology help to enable this? 

Since circulating tumor cells (CTCs) are malignant cells that are shed from the solid tumors and circulate in the bloodstream, the isolation and analysis of these cells from blood could help physicians to obtain this valuable information. However, this is not an easy task, because of their heterogeneity and extremely low numbers in comparison to blood cells, the isolation of these malignant cells from blood represents a major technological challenge. This is why our technology was carefully designed to have the necessary sensitivity to capture these cells; the CytoCatch™ platform has the sensitivity to isolate a single CTC from a background of 50 billion blood cells. By analyzing the captured cells, either by immunofluorescence or molecular techniques, the biological characteristics of the patient’s tumor can be identified. 

Hope this has been useful.

Finally, we take this opportunity to remind you that there are only 8 days left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙

Delee is building an assembly line

5 months ago

Hello everyone!

As you know, we are working intensely to begin the commercialization of our technology as a research use only device by late Q3/early Q4 of this year, where our initial customers will be research centers and pharma companies.

That’s why we are thrilled to announce that we are building our assembly line for the production of the CytoCatch™️ isolation platform and imaging system. This is a major milestone that will get us closer to the commercialization goal. Being able to assemble our devices in-house will help us considerably minimize production costs, while ensuring the production of a significant number of high-quality units.



There are less than 2 weeks until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

We want to thank everyone who has supported us by becoming investors in Delee, you have been a crucial part of our journey and accomplishments.


Delee Team 💙

2 weeks left to invest!

5 months ago

Hello everyone!

Only 2 weeks are left until Delee’s campaign ends. We want to thank everyone who has supported us by becoming investors in Delee. 

For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares.

And if you haven't made an investment yet, and you’re interested, you still have time to do so.

Thank you!

Delee Team 💙



Notice of Funds Disbursement

5 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, DELEE has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in DELEE be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Delee will be participating in StartX’s investor demo day

5 months ago

Hello everyone!

We are thrilled to announce that Delee will be participating in StartX’s investor demo day, which will be taking place on March 24rd. The format of this demo day will reach over 800 VCs, angel investors, and corporate partners. An average of 30+ follow-up meeting requests per company are received in the days following demo day.


We take this opportunity to remind you that only 2 weeks left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

We want to thank everyone who supported us by becoming investors in Delee, the best is yet to come. 


Delee Team 💙

3 weeks left to invest!

5 months ago

Only 3 weeks are left until Delee’s campaign ends. We want to thank everyone who has believed in us and became investors in Delee, we won't let you down.

For those who reserved shares during the TTW stage, remember that you only have this period of time to confirm your investment and receive your 10% of bonus shares.

And if you haven't made an investment yet, and you’re interested, there’s still time to do so.

Thank you!



Delee in the Cartier Impact Awards 2022

5 months ago

Hello everyone!


As a fellow of the Cartier Women’s Initiative, our CEO was invited to the Impact Awards held in Dubai on March 6, 2022, to commemorate the 15th anniversary of the Cartier Women’s Initiative. Liza was one of the seven laureates from around the world in the 2019 edition of the Cartier Women's Initiative Awards due to her work in Delee, which will positively impact the lives of many people from around the world. 



During these sessions, Liza had the opportunity of talking with several angel investors and managing partners of important VC firms with whom we will continue to be in contact and initiate a due diligence process to seek an investment that will allow us to complete our round.


We will keep you informed of further developments on this issue. Thank you for all your support!

Delee Team 💙

Notice of Material Change in Offering

6 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the DELEE offering. Here's an excerpt describing the specifics of the change:


Issuer is extending campaign to 04/06/22.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Delee's Newest Clinical Collaboration

6 months ago

Hello everyone!

We hope you are well.

We want to share with you a quick, but an important update. This week we established a new collaboration with Carlos Salazar Mejía M.D. and Omar Zayas Villanueva M.D., who are part of the oncology department of the University Hospital “Dr. José Eleuterio González”, one of the most prestigious hospitals in Mexico.



With this collaboration, we ensure the collection of the samples needed to complete the clinical study, and more importantly, we’ll be able to shorten the estimated time for its completion, expecting to have the results by mid-June. 


We will keep you informed regarding the progress of the clinical study.


Thank you for all your support!


Delee Team 💙

Notice of Funds Disbursement

6 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, DELEE has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in DELEE be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Delee's Clinical Trial Update 🚀

6 months ago

Hello everyone!

We want to share with you the progress we have made regarding our clinical study. Despite the surge in COVID-19 cases due to the Omicron variant, we were able to continue collecting and processing samples. Thus far, we have collected and processed 20% of the samples considered for the study, which include blood samples from prostate cancer patients at different stages and healthy donors. The technology has been working great in the clinical environment. Right now, we are holding talks with other medical institutions that can help us collect more samples in order to finish the clinical trial ahead of schedule, we’ll have information very soon.



The aim of this clinical study is to validate that our technology is able to discriminate between prostate cancer patients and healthy donors, and that it’s capable of identifying specific markers within the captured CTCs that serve as targets for novel targeted therapies, which will help physicians make information-driven decisions concerning treatment selection and treatment’s response assessment.


We want to thank all of you for all your support, the reason why we have been able to get so far. We’ll keep you updated on the progress of the trial. 


Delee Team.  

New Campaign Video

7 months ago

Hello everyone!

We invite you to watch our new video that we will be using to promote our campaign. Here it's highlighted why cancer blood tests are in need of a paradigm shift in order for them to play a bigger role in the diagnosis and treatment of cancer patients, and why we think our technology will revolutionize the way cancer is detected and managed. Hope you like it! Thank you for all your support.



Delee has started the development of a molecular panel for prostate cancer

7 months ago

Hello everyone!

As you are aware, the state-of-the-art technology that we've developed is capable of efficiently isolating and analyzing CTCs from blood. This technology was carefully designed to automatically process a blood sample and perform an immunofluorescence-based analysis over the captured cells, increasing assay reproducibility by eliminating human error. The performance of an immunofluorescence-based analysis allows the accurate enumeration of the cells captured, and helps identify specific markers and cellular structures by tagging fluorescently labeled antibodies, as seen in the following GIF (the micrographs constituting this GIF were taken with our imaging system).



However, one of the competitive advantages of our technology is that the collected cells are compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs. We are really excited because this week we’ve started the design of a molecular panel for prostate cancer based on polymerase chain reaction (PCR) technology.  



Previously, in one of our peer-reviewed scientific articles called: characterization of a novel automated microfiltration device for the efficient isolation and analysis of circulating tumor cells from clinical blood samples, we demonstrated that the captured cells isolated with our technology remain compatible with further molecular assays. This is of extreme importance, because we can identify specific gene mutations, only possible through these techniques, that make a patient sensitive or resistant to a targeted therapy. The ability of our technology for efficiently capturing CTCs from blood and the possibility of performing different types of analyses over the captured cells, will increase dramatically the amount of information obtained by physicians to provide a better diagnosis and management of cancer patients.


Thank you all for your support, we will keep you updated on our progress.  


Delee Team


The newest NCCN clinical practice guidelines in oncology for prostate cancer recommend the AR-V7 testing in CTCs

7 months ago

Previously, we talked about the importance of diagnosing cancer at early stages and how our technology can be introduced in the detection pipeline. However, the isolation and analysis of circulating tumor cells (CTCs) can also be used to identify specific markers within these cells in order to help guide treatment decisions. 


For instance, the most recent version of the NCCN clinical practice guidelines in oncology for prostate cancer, recommend the AR-V7 testing in CTCs to guide physicians in the treatment selection of metastatic castrate resistant prostate cancer patients that have already received abiraterone or enzalutamide therapies. This is of extreme importance because patients whose CTCs harbor the AR-V7 mRNA or the AR-V7 protein are more likely to benefit from taxane chemotherapy, whereas patients whose CTCs are negative for the AR-V7 mRNA or the AR-V7 protein respond better to novel hormonal therapies.


The NCCN guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions that currently apply to 97 percent of cancers affecting patients in the United States (National Comprehensive Cancer Network, 2021). The fact that the NCCN guidelines are recommending these tests underlines the impact that CTCs are having in the management of cancer patients, and therefore, validate the need for technologies like ours, technologies that can efficiently isolate and analyze these cells.


Beyond the identification of the AR-V7 in prostate cancer, the isolation and analysis of CTCs can be used to identify other markers that help guide treatment decisions, such as HER-2 in breast cancer, PD-L1 in lung cancer, and KRAS mutations in colorectal and lung cancer.  In the coming years, CTC tests will play a fundamental role in the personalization of cancer therapies and our technology will be the standard that powers these tests. 


Notice of Funds Disbursement

8 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, DELEE has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in DELEE be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Why we founded Delee

8 months ago

Cancer is one of the main leading causes of death worldwide, it affects millions of people everywhere and it is estimated that, in the next 20 years, the number of new registered cases and fatalities per year will increase to 30.2 M and 16.3 M, respectively. If you take a look at these numbers, it's very hard to find someone who hasn’t been affected by this disease. Either you were diagnosed with it, know someone who’s been diagnosed, or maybe even lost a loved one to cancer. Sadly, this reality has hit close to home too; my fellow co-founders, other members of the team, and myself have experienced very closely how cancer can forever change every aspect in a family’s life.


When we began our journey as entrepreneurs, Alejandro, Juan, and I, were aware of what cancer represented, and still does, as a global health issue. We wanted to combine our love for science and technology to find a solution that could help mitigate this problem. That’s why we decided to create our own company and focus on cancer blood tests which have played a critical role and still do in the diagnosis and treatment of cancer patients. However, the sensitivity and specificity of available cancer blood tests is far from ideal, which oftentimes leads to results that could mislead the clinical decisions physicians make regarding the diagnosis and management of their patients, impacting negatively in their survival chances.



The early days were difficult, we had to build and improve the first prototypes of our technology, while we were looking for funding that allowed us to continue with our research. But our efforts paid off, after finishing one of our first functional prototypes we were accepted into Y Combinator, where we raised our first round, which allowed us to accelerate the development of our technology. Thanks to this and the people who have invested in us, we have been able to create an innovative technology that allows the efficient isolation and analysis of circulating tumor cells (CTCs) from blood samples, in order to enable early cancer detection and provide an appropriate monitoring of the treatments’ effectiveness. What we have built will contribute to detecting cancer at stages where survival is more likely, while providing physicians with the necessary information to personalize each patient’s therapy and monitor its effectiveness throughout the course of their disease.


Thank you for believing in us!

Our CEO was interviewed for the KingsCrowd’s Founder Profiles series

8 months ago

Our CEO, Liza Velarde, was interviewed by KingsCrowd, the #1 Equity Crowdfunding Startup Data & Analytics Platform for their series of Founder Profiles where they talk to founders who are currently running an equity crowdfunding campaign. 


In this Profile she talks about the early days of the Delee, the cancer diagnostics market, business strategy, the future of the company, and her experience as a minority and underrepresented founder. 


You can access this Founder Profile with a Kingscrowd Starter Membership or by starting a free trial. 



Dr. Lauro Gómez on the Importance of Prostate Cancer Diagnosis

8 months ago

Hi Everyone! 

We want to share with you a video of Dr. Lauro Gómez, who is part of our medical and scientific advisory board. In the video he talks a little about the importance of prostate cancer diagnosis and how that impacts the administration of more specific therapies for each patient. We want to share with you a video where Dr. Lauro Gómez talks a little about the importance of prostate cancer diagnosis and how that impacts the administration of more specific therapies for each patient.


We are very grateful to all the people who have invested in us, your trust is what has allowed us to reach so many people in the medical community who are excited about our technology.

Sincerely,

Delee Team 💙

The next big step in Delee's history has begun with the pre-clinical trial underway

8 months ago

Greetings everyone, it is with great joy to inform you that today, December 3rd, we officially began our pre-clinical trial, where we will be validating our technology using samples from patients with prostate cancer at different stages and healthy controls. With this trial we will assess the feasibility of establishing a baseline in the levels of CTCs measured with our technology to discriminate between healthy individuals and cancer patients. Additionally, we will test the viability of identifying markers within CTCs in order for physicians to have reliable data at their disposal, helping them make information-driven decisions concerning treatment selection and treatment’s response assessment.

We are very grateful to all the people who have invested in us, your trust is what has allowed us to reach such an important milestone for our company.

We will keep everyone informed about the status of the pre-clinical trial in future updates that will be posted through this platform.

Sincerely,

Delee Team 💙

Just a few days away from starting our pre-clinical trial

8 months ago

We are only a few days away from starting our pre-clinical trial. Our technology will be initially validated in prostate cancer using patient samples at different stages and healthy controls. We are working very hard on the final details to get the best possible results.

Thanks to all the doctors who are collaborating with us and to the patients who will participate in this study. Also, special thanks to all our investors, without you none of this would have been possible.
We will keep everyone informed about the status of the pre-clinical trial in future updates that will be posted through this platform.

Sincerely,

Delee Team

Delee reaches $200k in investments! 🚀

9 months ago

We are excited to announce that our Reg CF crowdfunding campaign on StartEngine has reached the $200k milestone. 🚀


From the bottom of our hearts, massive thanks to all the people who are helping us revolutionize the way cancer is diagnosed and managed.


Keep following our campaign for more exciting updates, and if you can, spread the word with your friends and family. 🙏


Sincerely, 

Delee Team 💙


Delee Rated 4.8/5 By KingsCrowd’s Merlin Proprietary Startup Rating Algorithm, the #1 Equity Crowdfunding Startup Data & Analytics Platform

9 months ago

KingsCrowd, the #1 Equity Crowdfunding Startup Data & Analytics Platform, has announced that its Merlin Startup Rating algorithm has awarded Delee a rare 4.8/5 rating. KingsCrowd's analyst team has also named Delee as a coveted "Deal to Watch", placing it in the top 4% of the more than 700 active equity crowdfunding campaigns currently rated by KingsCrowd. 

KingsCrowd independently vets and analyzes startups across the entire online crowdfunding market and is used by more than 100,000 investors.

Interested parties can obtain a free digital copy of KingsCrowd’s full Delee Rating & Analysis Report. 

Highlights include:

  • Why Delee has been ranked a Deal to Watch
  • Both the Bull and Bear Cases of investing compiled by KingsCrowd's industry-leading analyst team. 
  • A comprehensive deep-dive into Delee's growth plans, management team, and KingsCrowd's proprietary Merlin Rating. 

Click here to read KingsCrowd’s Delee Rating & Analysis Report.


Delee did not solicit nor in any way compensate KingsCrowd for this analysis.


Revolutionizing cancer blood tests

9 months ago

For many years cancer blood tests have played a critical role in the diagnosis and treatment of cancer patients. However, even though an important number of tumor markers can be currently measured by conventional techniques, their sensitivity and specificity is far from ideal, which oftentimes leads to results that could mislead the clinical decisions physicians make regarding the diagnosis and management of their patients. 


Nowadays, most of the cancer blood tests employed as auxiliaries in the diagnosis of cancer and monitoring of the applied treatments’ effectiveness measure protein tumor markers levels, such as PSA, CA-125, and AFP. These markers may be elevated in people that do not have cancer, furthermore, not every person with cancer will have an elevated level of the corresponding tumor marker. For instance, when carrying out the PSA test, which measures the amount of PSA in blood and is widely used for prostate cancer screening, only 21% of men with prostate cancer have increased levels of PSA, whereas 11% of men with increased levels of PSA do not have cancer. This is only one of the many examples that highlights the need to develop cancer blood tests capable of providing more accurate information regarding each patients’ cancer.


The isolation and analysis of circulating tumor cells (CTCs) from blood has the potential to address these issues and overcome the limitations of currently available cancer blood tests, in order for physicians to have more reliable data at their disposal, helping them make information-driven decisions concerning cancer diagnosis, treatment selection, treatment’s response assessment, and recurrence monitoring. However, due to their extremely low concentration compared to other cellular blood components, identifying CTCs in blood is like finding a needle in a haystack, making it a major technological challenge.


Delee is revolutionizing cancer blood tests, with the Cytocatch™  isolation platform and imaging system. This state-of-the-art technology is capable of efficiently isolating and analyzing CTCs from blood. Through a set of fully automated processes and a powerful AI, this platform detects, classifies, and quantifies CTCs based on their morphology and the expression of specific markers, increasing the reliability and reproducibility of the test by preventing human error and cell loss due to manual steps. The captured CTCs remain compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess their genetic characteristics. Finally, the images of the CTCs captured from each patient can be stored in a database that can be accessed remotely so lab and clinical teams can review them from anywhere at any time, improving communication and collaboration between physicians regardless of geographical constraints.



We are deeply grateful for your unwavering support, we know that none of this would have been possible without you. If you can, keep spreading the word with your friends and family. Thank you!


Sincerely,

Delee Team 💙

The CytoCatch™ technology is about to start testing with patient samples

9 months ago

Hello everyone!


On behalf of our team, I would like to thank all of you for believing in our company. This keeps us striving towards our goal of having our device in every hospital in order to save lives.


Your immense support has helped us in finishing the analytical validation of our devices, which are necessary to begin with the pre-clinical study needed to obtain our clinical validation using blood samples from patients with prostate cancer. In the next couple of weeks we will be starting this validation after receiving samples from various hospitals we are collaborating with 🚀.


We want to share with you the GIF below, where you can identify the captured CTCs (green dots) after processing a blood sample with our isolation platform. These results are possible thanks to the optimal performance of our technology 💪. The importance of this is that all the processes and algorithms dedicated to the correct operation of our devices are working and their operation has been validated after performing our latest tests. This evidence supports that our technology is ready to take the next step which is clinical validation 🔥.



Once again, thank you very much! And if you can, spread the word regarding our campaign.


Sincerely, 


Liza Velarde

Delee Corp.

Most Recent CTC Market Data

10 months ago

Hello everyone!


There is a new analysis report about the circulating tumor cells market, it was conducted by Grand View Research, and we want to share with you some key points that we are sure you’ll find interesting.


For the current year, the global circulating tumor cell market is expected to be valued at $9.3 billion USD. The CTC market is split into the clinical and research segments. In 2021, the research segment will account for 75% of the overall CTC market, with academic research centers and pharmaceutical companies as the main customers. The use of CTC technologies will have an extraordinary value for these entities, because of its great potential for studying the biology of cancer, identifying potential therapeutic markers within CTCs, and aiding drug development. On the other hand, the clinic segment will account for 25% of the overall CTC market, and although the share is smaller, it is expected to grow in the next few years, due to the upcoming increase of physicians adopting new applications that involve the use of CTC technologies.


It’s expected for the market to reach a valuation of $18.3 billion USD by 2027. This growth is mainly driven by the imminent increase of the cancer cases that will occur in the following years. There is a clear necessity to find new biomarkers that can provide better information for the timely diagnosis and management of cancer; this is why we are aiming to commercialize the CytoCatch™ isolation platform and imaging system as research tools. Our technology possesses the specificity and sensibility required to successfully isolate and analyze CTCs from blood, which may enable numerous applications that can be seized by said research centers and pharmaceutical companies, and later on by professionals and institutions in the clinical field. 


From the bottom of our hearts, thank you for helping us on our mission by supporting our crowdfunding campaign and for spreading the word with your friends and family. 


Sincerely, 

Delee Team 💙 

Notice of Funds Disbursement

10 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, DELEE has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in DELEE be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Delee has been selected as a UCSF Health Hub Quarterfinalist 🔥

11 months ago


We are honored to be chosen as a UCSF Health Hub Quarterfinalist in the New Life Sciences Diagnostic category 🥳. The UCSF Health Awards honors outstanding technologies that are radically transforming healthcare and improving patient outcomes. This event is sponsored by some of the most renowned big tech and big pharma companies, such as Eli Lilly, Genentech, Johnson and Johnson, and Astellas. Our application was selected among the 8 finalists by a panel of 300+ eminent judges that are experts in the field 😎. This recognition further validates the importance of developing a technology for early cancer detection and monitoring the applied treatments’ effectiveness.


Delee reaches $100k in investments! 🚀

11 months ago

We are thrilled to announce that our Reg CF crowdfunding campaign on StartEngine has raised over $100k from 216 investors in less than a week! 🔥


Thank you to all the people who are helping us revolutionize the way cancer is diagnosed and managed. We are working really hard so our technology could benefit as many patients as possible. 🙏


Keep following our campaign for more exciting updates. 


Sincerely, 


Delee Team 💙

Our campaign is officially live!

11 months ago

Dear Investors,


Our crowdfunding campaign on StartEngine is officially live! 🚀 


If you reserved shares during our TTW remember that the bonus shares you received will stack with the bonus shares offered during the campaign. If you confirm your investment in the first 72 hours after launch you will receive at least an additional 10% bonus shares regardless of the amount invested. If you couldn’t reserve during our TTW you can also receive the bonus shares if you invest during the first 72 hours after launch.


Thank you very much for all the incredible support you have given us and for spreading the word of our campaign with others, it truly means a lot 🙏. Exciting times are ahead, we are glad to have you on board to enjoy them together.

 
Sincerely,

Delee Team 💙

We are a few days away from launching!

11 months ago

Dear investors,

As you may know, at the moment, we are still in the TTW stage; but we are very excited to announce that we are just a few days away from the launch of our StartEngine campaign 🚀.

On behalf of our team, I would like to thank all of you for reserving your investment with us. It means the world to know that so many people believe in our work and are joining us on this journey. We are ending this phase with over $275k in reservations 😀. Rest assured that your support is greatly appreciated and it keeps us moving forward 💪.  Stay tuned, because once the campaign goes live, if you confirm your investment you can increase the number of bonus shares that you got during our TTW.

Once again, thank you very much! And please, stay safe.


Sincerely, 

Liza Velarde

Delee Corp.

The final version of the CytoCatch™️ imaging system is finally here 🙌

about 1 year ago

We hope that you and yours are well and safe 😄

 

A few weeks ago we announced that the final version of the CytoCatch™️ isolation platform had been completed. Today we have another exciting announcement, the final version of the CytoCatch™️ imaging system is finally completed 🥳

 

microscope 1 gif


After concluding our previous crowdfunding campaign we found ourselves in a very difficult situation, with the pandemic raging we had to coordinate with every member of our team to efficiently work both from our homes and lab. To be able to share this news with you fills every member of the team with a tremendous amount of joy. 

 

The CytoCatch™️ imaging system is the most complex unit that constitutes our technology. This system was specially designed to acquire high-resolution micrographs of the CTCs that were previously captured by our isolation platform. It possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. All these processes, ranging from image acquisition to image analysis, are fully automated, which increases the reliability and reproducibility of the assay by preventing human error.

 

 

microscope 2 gif c


Our StartEngine campaign launching soon, remember that you can still reserve your investment and receive 10% bonus shares

 

We are deeply grateful for your unwavering support, we know that none of these amazing achievements would have been possible without each and every one of you. From the bottom of our hearts, thank you!

 

Sincerely, 

 

Delee Team 💙

Delee has started the analytical validation of the CytoCatch™ isolation platform.

about 1 year ago

Hello everyone! 


We hope you’re doing well 😄.


We would like to share with you that last week we began the analytical validation of the final version of the CytoCatch™ isolation platform, one of the two devices that constitute our technology and makes it possible to isolate CTCs from other blood components. 



This validation is fundamental for any medical or scientific device built to measure an analyte (the constituent of the sample to be analyzed, in our case the CTCs). The tests carried out during this validation are designed to ensure that our platform’s performance is optimal and the results obtained are reproducible. Here, our device will be extensively tested to assess key parameters, such as capture efficiency, purity, sensitivity, working range, precision, and accuracy. This has to be made before the device’s clinical validation, where a clinical study is going to be conducted in order to collect clinical data. 


Even though this is just the beginning, and this validation will last for several months, we are thrilled because the first tests carried out yielded very positive results. Our device consistently had over 94% capture efficiency when processing blood samples of 7.5 mL spiked with 100 cancer cells. This means that our device was able to capture over 94 of these cells in every run performed, which is in line or even higher than our competitors’ yield 😎.



We are deeply thankful to all the people who already reserved their investment 🤗. At the moment, we are still in the Test The Waters (TTW) stage, in which you can reserve your investment without committing until the campaign goes officially live. If you reserve during the TTW stage you will receive 10% bonus shares when you confirm the investment.


Once again, thank you for all your support!


Sincerely, 


Delee Team 💙

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}